RU2018119120A - D-пролиновые производные в качестве агента, уменьшающего количество sap - Google Patents

D-пролиновые производные в качестве агента, уменьшающего количество sap Download PDF

Info

Publication number
RU2018119120A
RU2018119120A RU2018119120A RU2018119120A RU2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A RU 2018119120 A RU2018119120 A RU 2018119120A
Authority
RU
Russia
Prior art keywords
compound
pharmaceutical composition
sap
composition according
amount
Prior art date
Application number
RU2018119120A
Other languages
English (en)
Russian (ru)
Inventor
Алексис Дени
Оливье Мирге
Жером Тум
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of RU2018119120A publication Critical patent/RU2018119120A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018119120A 2015-10-27 2016-10-25 D-пролиновые производные в качестве агента, уменьшающего количество sap RU2018119120A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518950.9 2015-10-27
GBGB1518950.9A GB201518950D0 (en) 2015-10-27 2015-10-27 Compound
PCT/EP2016/075632 WO2017072099A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as sap depleting agent

Publications (1)

Publication Number Publication Date
RU2018119120A true RU2018119120A (ru) 2019-11-28

Family

ID=55130261

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018119120A RU2018119120A (ru) 2015-10-27 2016-10-25 D-пролиновые производные в качестве агента, уменьшающего количество sap

Country Status (12)

Country Link
US (1) US10328052B2 (enExample)
EP (1) EP3368532B1 (enExample)
JP (2) JP6789288B2 (enExample)
KR (1) KR20180067559A (enExample)
CN (1) CN108368095B (enExample)
AU (1) AU2016345462A1 (enExample)
BR (1) BR112018008582A2 (enExample)
CA (1) CA3002710A1 (enExample)
ES (1) ES2781550T3 (enExample)
GB (1) GB201518950D0 (enExample)
RU (1) RU2018119120A (enExample)
WO (1) WO2017072099A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) * 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound

Also Published As

Publication number Publication date
EP3368532B1 (en) 2020-01-15
US10328052B2 (en) 2019-06-25
CA3002710A1 (en) 2017-05-04
KR20180067559A (ko) 2018-06-20
JP2018531967A (ja) 2018-11-01
CN108368095A (zh) 2018-08-03
GB201518950D0 (en) 2015-12-09
US20190060274A1 (en) 2019-02-28
JP7053762B2 (ja) 2022-04-12
JP2021035963A (ja) 2021-03-04
BR112018008582A2 (pt) 2018-10-30
ES2781550T3 (es) 2020-09-03
WO2017072099A1 (en) 2017-05-04
JP6789288B2 (ja) 2020-11-25
AU2016345462A1 (en) 2018-04-26
CN108368095B (zh) 2021-06-08
EP3368532A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
RU2017105353A (ru) Соединения
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
RU2018133298A (ru) Способы применения агонистов fxr
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2013541583A5 (enExample)
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
JP2023553253A5 (enExample)
RU2018130097A (ru) Лечение экземы кистей
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
JP2015512948A5 (enExample)
RU2017126153A (ru) Фармацевтическая комбинация
JP2017514829A5 (enExample)
RU2019102757A (ru) Производные этинила
RU2013126798A (ru) Комбинированная терапия дексаметазоном
JP2013542262A5 (enExample)
JP2019513151A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20191028